SB203580
Negotiable Min Order Quantity Unit
- Required Quantity
-
- Place of Origin
- China
- Payment Terms
- Negotiable
- Production method
- Negotiable
- Shipping / Lead Time
- Negotiable / Negotiable
- Keyword
- sb203580, 152121-47-6
- Category
- Pharmaceutical Intermediates
Beijing Cooperate Pharmaceutical Co.,Ltd
China
- Verified Certificate
-
12
| Product name | SB203580 | Certification | - |
|---|---|---|---|
| Category | Pharmaceutical Intermediates | Ingredients | - |
| Keyword | sb203580 , 152121-47-6 | Unit Size | - |
| Brand name | - | Unit Weigh | - |
| origin | China | Stock | - |
| Supply type | - | HS code | - |
Product Information
Prouduct Name:SB203580
Chemical Name:4-[5-(4-Fluorophenyl)-2-[4-(methylsulfonyl)phenyl]-1H-imidazol-4-yl]pyridine
M.Wt: 377.43
Formula: C21H16FN3OS
appearance:yellow powder
Solubility: Soluble to 25 mM in DMSO and to 100 mM in 1eq. HCl
Purity:>98%
Storage: Desiccate at +4°C
CAS No: 152121-47-6
SB203580 inhibits the IL-2-induced
proliferation of primary human T cells, murine CT6 T cells, or BAF F7 B cells
with an IC50 of 3–5 μm. SB203580 also inhibits IL-2-induced p70S6 kinase
activation, although the concentration required is slightly higher with an IC50
above 10 μm. SB203580 also inhibits the activity of PDK1 in a dose-dependent
manner with an IC50 in the 3–10 μm range. SB203580 inhibits p38-MAPK
stimulation of MAPKAPK2 with an IC50 of approximately 0.07 μM, whereas inhibits
total SAPK/JNK activity with an IC50 of 3–10 μM. SB203580 at higher
concentrations activates the ERK pathway, which subsequently enhances NF-κB transcriptional
activity. SB203580 induces autophagy in human hepatocellular carcinoma (HCC)
cells.
B2B Trade
| Price (FOB) | Negotiable | transportation | - |
|---|---|---|---|
| MOQ | Negotiable | Leadtime | Negotiable |
| Payment Options | Negotiable | Shipping time | Negotiable |
- President
- liuchang
- Address
- http://www.cooperate-pharm.com
- Product Category
- Industrial Supplies,Pharmaceutical Intermediates
- Year Established
- 2016
- No. of Total Employees
- 51-100
- Company introduction
-
<p>
Beijing Cooperate Pharmaceutical Co.,Ltd is a high-tech company specializing in pharmaceutical and advanced material, involving API,pharmaceutical intermediates and petrochemical additives . we are the direct producer of some kinds of new pharmaceutical intermediates products what can be use for the treatment of disease of heart head blood-vessel, cancer,mental sickness and respiratory disease .Most of our research staff had been in pharmaceutical field for more than 5-10 years, so our professional and experienced team will supply you with high quality products, competitive prices and excellent services. In 2016 ,our company establish a new department for sale pharmaceuticals and chemical solvent abroad,now we have all of the license about import and export trade ,so if you have any new chemicals want to find or develop in China, please tell us by email or telephone , we will provide attentive service for the purpose to meet the demand of customers, spare no effort to create value for customers.
Beijing Cooperate Pharmaceutical is now headquartered in Beijing,and we have factory and laboratory of ourselves in Hebei and Shangdong province ,equipped with SEM, AAS, LPSA, LC-MS, FTIR, digital melting point apparatus and other basic test equipment.now we can supply from gram to metric ton products with high-efficiency and competitive cost controlling.contact us freely now ,you will find more surprising here .
- Main Markets
-
Bangladesh
Japan
U. Kingdom
U.S.A
- Main Product
Related Products
Cas 24131-07-5
3-Iodo-N-phenylcarbazole, CAS NO.: 502161-03-7
Betamethasone 17-valerate
16-beta Methyl Epoxide
Drug, medicine, API, pharmaceutical raw material, surgical dressing
